Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rank in Stocks #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Share Price
$0.00047446
Market Cap
$82.80
Change (1 day)
0.00%
Change (1 year)
-98.16%
Country
FR
Trade Neovacs S.A. (ALNEV)

Category

Dividend history for Neovacs S.A. (ALNEV)
Neovacs S.A. (stock symbol: ALNEV) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Neovacs S.A. (ALNEV) from 2026 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
Not enough data for the provided dates.
List of all dividend payments
Year Dividend Change
Not enough data for the provided dates.
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
52.00%
DK
0.00%
US
5.00%
US
29.00%
BE
0.00%
NL